Fed. Circ. Urged To End 'Unrealistic' Obviousness Test
By Tiffany Hu ( May 20, 2020, 5:06 PM EDT) -- A biotech trade group is urging the Federal Circuit to use a patent case involving Amarin Pharma's blockbuster heart drug Vascepa to end the court's "unrealistic" approach to determining whether a patent is invalid that "tilts the scales in favor of obviousness."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.